Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction:

Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues to be required in a substantial proportion of patients. This review highlights emerging strategies aimed at personalizing treatment and improving outcomes.

Why was this review needed?

• Management of ASUC has remained largely unchanged for nearly 20 years.
• One-third of patients fail intravenous corticosteroid therapy.
• Colectomy and mortality remain significant despite current treatment.
• Early identification of steroid non-responders remains challenging.
• Personalized treatment strategies are needed to improve outcomes.

Key Takeaways:

• Intravenous corticosteroids remain the first-line therapy, while infliximab and ciclosporin are the only rescue therapies supported by robust randomized trial evidence.
• Up to one-third of patients fail steroid therapy, requiring early rescue treatment or surgery.
• Colectomy remains necessary in 10–15% of patients during the initial admission, with the risk increasing after subsequent hospitalizations.
• JAK inhibitors are emerging as promising rescue therapies, although larger prospective trials are still required.
• Pharmacokinetic-guided infliximab dosing may optimize treatment response in selected patients.
• Risk prediction tools, such as ADMIT-ASC, may help identify high-risk patients early and facilitate individualized treatment decisions.
• Future management is expected to shift from a uniform "wait-to-fail" approach toward early risk stratification and precision medicine.

Clinical Impact:

The future management of ASUC is likely to focus on earlier identification of high-risk patients, individualized rescue therapy, and optimized biologic dosing rather than waiting for treatment failure. This strategy has the potential to reduce colectomy rates and improve long-term outcomes.

Bottom Line:

Acute severe ulcerative colitis remains a medical emergency with substantial morbidity. The next major advance will be personalized, risk-based treatment, integrating predictive models, optimized biologic therapy, and novel agents such as JAK inhibitors to improve patient outcomes.